Deplin vs. OTC Folate: Key Differences
Deplin (L-methylfolate) is the active, already-metabolized form of folate that bypasses the need for enzymatic conversion, while over-the-counter folic acid is a synthetic compound requiring multi-step hepatic reduction before becoming biologically active.
Chemical Structure and Metabolism
Folic acid is a fully oxidized, synthetic form of vitamin B9 (pteroylglutamic acid) that does not exist naturally in foods 1. It lacks coenzyme activity and must undergo enzymatic reduction in the liver to become metabolically active tetrahydrofolate, and ultimately to L-5-methyltetrahydrofolate (L-5-MTHF) 2.
L-methylfolate (Deplin) is the naturally occurring, predominant form of folate found in circulation and the only species normally transported into peripheral tissues for cellular metabolism 2. It is immediately bioavailable and requires no metabolic conversion 3.
Bioavailability and Effectiveness
Both compounds demonstrate comparable physiological activity and absorption at equimolar doses 2. However, L-5-MTHF may be more effective in certain populations:
- Studies show L-5-MTHF is at least as effective as folic acid in improving folate status, measured by blood folate concentrations and functional indicators like plasma homocysteine 2
- In one randomized controlled trial, low-dose L-MTHF (113 μg) was actually more effective than equimolar folic acid (100 μg) in lowering homocysteine at 24 weeks (14.6% vs 9.3% reduction, p<0.05) 4
- Individuals with genetic polymorphisms affecting folate metabolism (such as MTHFR variants) or absorption may benefit more from 5-MTHF than folic acid 5
Clinical Advantages of L-Methylfolate
L-5-MTHF offers several theoretical advantages over folic acid 5, 3:
No masking of B12 deficiency: Unlike folic acid, L-5-MTHF does not mask the hematological indicators of vitamin B12 deficiency, reducing risk of neurological complications 2, 5
No unmetabolized folic acid: Folic acid appears unmetabolized in circulation at doses >200 μg, and individuals show wide variations in their ability to reduce it 5. L-5-MTHF avoids this issue entirely
Reduced drug interactions: L-5-MTHF may have fewer interactions with medications that inhibit dihydrofolate reductase 2
No tolerable upper intake level: Unlike folic acid, 5-MTHF has no established upper limit 5
Immediate availability: Does not require hepatic transformation, making it immediately available to mother and fetus 3
Standard Dosing Context
For neural tube defect prevention, guidelines recommend 0.4-0.8 mg (400-800 μg) daily folic acid for all women of childbearing age 6, 7. The FDA-approved folic acid dosing for therapeutic use ranges up to 1 mg daily, with maintenance doses of 0.1-0.8 mg depending on patient population 1.
Important Caveats
- For NTD prevention specifically, the robust evidence base supports folic acid supplementation 6. There is a lack of clinical studies evaluating 5-MTHF efficacy specifically for NTD prevention 8
- Most guideline recommendations are based on folic acid studies, not L-methylfolate 6, 7
- L-5-MTHF is available as a calcium salt (Metafolin®) with adequate stability for supplementation 2
- Deplin is typically prescribed at higher doses (7.5-15 mg) for adjunctive treatment of depression, not for standard folate supplementation 9
Clinical Bottom Line
For general folate supplementation and NTD prevention in average-risk women, standard OTC folic acid (400-800 μg) remains the evidence-based recommendation 6, 7. Consider L-methylfolate (Deplin) for patients with:
- Known MTHFR polymorphisms or other folate metabolism genetic variants
- Medications inhibiting dihydrofolate reductase
- Concerns about vitamin B12 deficiency masking
- Documented poor response to folic acid supplementation
- Depression requiring adjunctive folate therapy
The choice should account for cost (L-methylfolate is significantly more expensive as a prescription product) and the fact that the extensive safety and efficacy data for NTD prevention specifically comes from folic acid trials 6.